Journal for ImmunoTherapy of Cancer

Titel Veröffentlichungsdatum Sprache Zitate
Just how transformative will AI/ML be for immuno-oncology?2024/03/01English
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma2023/02/01English
NKG2A+CD8+T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma2024/01/01English
LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy2024/01/01English
Multimodal profiling of chordoma immunity reveals distinct immune contextures2024/01/01English
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders2024/01/01English
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma2024/01/01English
Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody2023/07/01English
Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus2023/06/01English
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers2023/06/01English
‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies?2022/12/01English
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy2023/01/01English
Next-generation ctDNA-driven clinical trials in precision immuno-oncology2023/01/01English
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer2024/04/01English
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors2024/04/01English
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma2024/04/01English
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy2024/04/01English
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C2024/04/01English
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer2024/04/01English
Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides2024/04/01English
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment2024/04/01English
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma2024/04/01English
Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ12024/04/01English
Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway2024/04/01English
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease2024/04/01English
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer2024/04/01English
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials2024/04/01English
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors2024/04/01English
Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayedet al2024/04/01English
Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchiet al2024/04/01English